Left atrial appendage closure increases acute atrial pressure without long-term structural impact. Learn more about these ...

Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.

If you are wondering whether AtriCure at around $40 a share is a smart buy or a value trap, you are not alone. That is exactly what we are going to unpack here. The stock is up 7.4% over the last ...

AtriCure, Inc. , a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced ...

On December 16, J.P. Morgan analyst Lilia-Celine (Lily) reiterated her bullish stance on AtriCure (NASDAQ:ATRC).

Columbus Regional Health Heart & Vascular announced that its cardiovascular services team recently completed its 100th ...

Boston Scientific Corporation is rated a Hold with double-digit revenue growth and margin expansion. Learn more about BSX ...

Boston Scientific BSX has a stretched valuation, reflected in its Value Score of C. Shares of the company are trading at a ...

Boston Scientific Corporation (NYSE:BSX) is one of the best healthcare AI stocks to buy now. On December 12, TD Cowen ...

BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.

A session at the AHA Scientific Sessions 2025 focused on dilemmas related to antithrombotic therapy following catheter ablation in patients with AF.

Learn more about whether AtriCure, Inc. or QuidelOrtho Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.